Literature DB >> 10700446

Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery.

R Q Miao1, H Murakami, Q Song, L Chao, J Chao.   

Abstract

Kallistatin, a serine proteinase inhibitor (serpin), is expressed in the endothelial and smooth muscle cells of blood vessels. The potential function of kallistatin in vascular biology was investigated by studying its role in the proliferation and migration of cultured primary aortic vascular smooth muscle cells (VSMCs) in vitro and in neointima formation in rat artery after balloon angioplasty in vivo. Exogenous kallistatin induced a >2-fold increase of VSMC proliferation and cell growth as measured by [(3)H]thymidine incorporation and cell counts and a 2.3-fold increase of cell migration in modified Boyden chambers. In balloon-injured vessels, endogenous kallistatin mRNA and protein levels increased up to 10-fold as determined by competitive polymerase chain reaction and by ELISA. Intense staining of kallistatin mRNA was identified in the proliferating VSMCs of balloon-injured arteries during cell migration from media to neointima by in situ hybridization histochemistry and immunohistochemistry. We observed an induction of kallistatin expression by platelet-derived growth factor (PDGF) and upregulation of p42/44 mitogen-activated protein kinase (MAPK) activity by kallistatin in cultured VSMCs. Conversely, adenovirus-mediated transfer of kallistatin antisense cDNA into cultured VSMCs inhibited PDGF-induced p42/44 MAPK activity and cell proliferation. Furthermore, local delivery of adenovirus carrying kallistatin antisense cDNA significantly downregulated kallistatin mRNA levels and attenuated neointima formation in balloon-injured rat arteries in vivo. These results indicate that kallistatin may play an important role in mediating PDGF-induced MAPK pathway on VSMC proliferation and in neointima formation after balloon angioplasty.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10700446     DOI: 10.1161/01.res.86.4.418

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  11 in total

1.  Human tissue kallikrein 1 gene delivery inhibits PDGF-BB-induced vascular smooth muscle cells proliferation and upregulates the expressions of p27Kip1 and p2lCip1.

Authors:  Hui-Zhen Yu; Liang-di Xie; Peng-li Zhu; Chang-sheng Xu; Hua-jun Wang
Journal:  Mol Cell Biochem       Date:  2011-09-30       Impact factor: 3.396

2.  Bladder smooth muscle organ culture preparation maintains the contractile phenotype.

Authors:  Tanchun Wang; Derek M Kendig; Shaohua Chang; Danielle M Trappanese; Samuel Chacko; Robert S Moreland
Journal:  Am J Physiol Renal Physiol       Date:  2012-08-15

3.  Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling.

Authors:  Yuying Liu; Grant Bledsoe; Makato Hagiwara; Bo Shen; Lee Chao; Julie Chao
Journal:  Am J Physiol Renal Physiol       Date:  2012-07-18

4.  Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection.

Authors:  Shiou-Ling Lu; Chiau-Yuang Tsai; Yueh-Hsia Luo; Chih-Feng Kuo; Wei-Chieh Lin; Yu-Tzu Chang; Jiunn-Jong Wu; Woei-Jer Chuang; Ching-Chuan Liu; Lee Chao; Julie Chao; Yee-Shin Lin
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

5.  Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation.

Authors:  Hang Yin; Lin Gao; Bo Shen; Lee Chao; Julie Chao
Journal:  Hypertension       Date:  2010-06-21       Impact factor: 10.190

6.  Temporal PTEN inactivation causes proliferation of saphenous vein smooth muscle cells of human CABG conduits.

Authors:  Amit K Mitra; Guanghong Jia; Deepak M Gangahar; Devendra K Agrawal
Journal:  J Cell Mol Med       Date:  2008-03-19       Impact factor: 5.310

7.  Increased serum kallistatin levels in type 1 diabetes patients with vascular complications.

Authors:  Alicia J Jenkins; Jeffrey D McBride; Andrzej S Januszewski; Connie S Karschimkus; Bin Zhang; David N O'Neal; Craig L Nelson; Jasmine S Chung; C Alex Harper; Timothy J Lyons; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-09-22

8.  Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression.

Authors:  Bo Shen; Robert S Smith; Yi-Te Hsu; Lee Chao; Julie Chao
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

9.  Kallistatin correlates with inflammation in abdominal aortic aneurysm and suppresses its formation in mice.

Authors:  Yuchen He; Yanshuo Han; Jia Xing; Xiaoyue Zhai; Shiyue Wang; Shijie Xin; Jian Zhang
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

10.  Kallistatin exerts anti-lymphangiogenic effects by inhibiting lymphatic endothelial cell proliferation, migration and tube formation.

Authors:  Caiqi Ma; Haofan Yin; Jun Zhong; Yang Zhang; Chuanghua Luo; Di Che; Zhenzhen Fang; Lei Li; Shuxing Qin; Jieying Liang; Weiwei Qi; Zhonghan Yang; Ti Zhou; Jianxing Ma; Xia Yang; Guoquan Gao
Journal:  Int J Oncol       Date:  2017-04-20       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.